University of Florida
2004 Mowry Road CTRB
Gainesville, FL 32610
United States
The University of Florida (UF) is one of twenty-two Type 1 Diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Michael Haller, MD, the TrialNet team at UF is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.
Our Team
Desmond Schatz, MD
Michael Haller, MD
Mark Atkinson, PhD
Laura Jacobson, MD
Jennifer Hosford, MPH
PD Towe
John Marks
"Our mission is to improve the lives of patients and families affected by type 1 diabetes. Until there is an effective means of preventing and reversing type 1 diabetes, we will continue to work towards making that dream a reality"-Michael Haller, MD, University of Florida
Regional Affiliates
Affiliates provide opportunities for people who do not live near a TrialNet Clinical Center. The affiliate sites listed below work with UF to offer convenient participation in our research programs
"Screening is the first step on the pathway to prevention. Those who test positive for an increased risk may be able to join other research studies testing ways to delay and prevent the disease. Without prevention, there can be no cure" Desmond Schatz, MD, University of Florida
Research Studies
If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More
Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More
We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D. Details
TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 or stage 2), and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression. Details
If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More
TrialNet is testing the safety of a new treatment, NNC0361-0041, in adults diagnosed with type 1 diabetes (T1D) in the past 48 months. This is a Phase 1 study, which means it is the first time this treatment is being tested for safety in people. If this study results in no safety concerns, we plan to conduct a larger study to see if this same treatment can slow down or stop T1D in people at high risk, before clinical diagnosis. More
